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INTRODUCTION
Traditional therapy for iliofemoral deep venous thrombo-
sis (DVT) has been systemic heparin followed by oral war-
farin. Despite widespread use of this method, the results have
been largely inadequate in terms of rapid resolution of symp-
toms, recanalization of long-segment venous occlusions, and
long-term disability from chronic venous insufficiency (1-4).
Thrombolysis for DVT, if performed soon after the onset of
symptoms, has the potential to prevent damage to the deep
valves, thus maintaining the integrity and preventing post-
thrombotic complications (4-9). During the past several years,
catheter-directed thrombolysis and endovascular stents have
been used to treat extensive lower extremity DVT, as an alter-
native to conservative anticoagulation therapy or surgical
thrombectomy, in selected cases. 
Thrombosis due to compression of the left common iliac
vein by the overlying right common iliac artery was first char-
acterized by May and Thurner in 1957 (10). With the advent
of catheter-directed thrombolysis, iliac vein compression syn-
drome (IVCS) is emerging as a frequent finding at venogra-
phy after iliofemoral vein thrombolysis. The term “hyperco-
agulable state” is generally used to denote any condition in
which the normal balance between clotting and anticlotting
mechanisms becomes altered in such a way that the patient
is predisposed to thrombus formation. There are a number
of conditions that can lead to a hypercoagulable state. Proteins
C and S deficiencies are frequently described as causes of the
hypercoagulable states (9, 11-19). Although instances of arte-
rial thromboses have been reported, proteins C and S defi-
ciencies have frequently been associated with venous throm-
boembolic events (9, 11-17).
The purpose of this study was to evaluate the early outcome
of endovascular management in patients with iliofemoral
DVT due to IVCS and protein C and/or S deficiency.
MATERIALS AND METHODS
Patients
A total of consecutive 47 patients with DVT were seen in
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Endovascular Management of Iliofemoral Deep Venous Thrombosis 
due to Iliac Vein Compression Syndrome in Patients with Protein C
and/or S Deficiency
The purpose of this study was to evaluate the early outcome of endovascular man-
agement in patients with iliofemoral deep venous thrombosis (DVT) due to iliac
vein compression syndrome (IVCS) and protein C and/or S deficiency. Between
September 2000 and January 2003, catheter-directed thrombolysis was performed
in 11 patients with a diagnosis of acute iliofemoral DVT: 7 with protein C and/or S
deficiency and 4 without protein C and/or S deficiency. After thrombolysis, the
diagnosis of IVCS was confirmed in 6 patients: 4 with protein C and/or S deficien-
cy and 2 without protein C and/or S deficiency. Further intervention consisted of
angioplasty and stent placement was performed. Four patients with IVCS and pro-
tein C and/or S deficiency were included in this study. The immediate technical
and clinical success rates were 100% in all 4 patients. There were no complica-
tions or clinically detectable pulmonary emboli. This initial experience suggests
that endovascular management of iliofemoral DVT due to IVCS in patients with
protein C and/or S deficiency is safe and effective.
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our department between September 2000 and January 2003.
The diagnosis of DVT was confirmed by characteristic clin-
ical, color Doppler ultrasound and/or conventional venogra-
phic findings. Of these, 10 patients (21.3%) were diagnosed
with DVT associated with protein C and/or S deficiency.
Hypercoagulability studies were done before thrombolysis
and systemic anticoagulation therapy. Antigenic protein C
and S levels were measured using human protein C/S ‘NL’
NANORIDTM radial immunodiffusion kit (the Binding Site
Ltd, Birmingham, U.K.), and the diagnosis of protein C and
S deficiencies was confirmed if antigenic protein C and S lev-
els were less than 60% of normal. In this study, 3 of the 10
patients with protein C and/or S deficiency did not receive
catheter-directed thrombolysis: due to an isolated infrainguinal
DVT (1) and a chronic DVT (2). Seven patients with acute
iliofemoral DVT and protein C and/or S deficiency were treat-
ed with catheter-directed thrombolytic therapy, and 4 with
the diagnosis of IVCS (compression of the left iliac vein by
the right iliac artery) after thrombolysis were included in this
study. There was no family history of DVT in all 4 patients.
We did not performed family studies for protein C and/or S
deficiency, because not all patients with these deficiencies will
experience episodes of thrombosis and low levels of either
factor by itself in an asymptomatic patient are not an indi-
cation for anticoagulation. Informed consent was obtained
in all patients after the risks and benefits of treatment were
fully explained. 
Procedure 
Local catheter-directed thrombolytic therapy with uroki-
nase (Green Cross Co., Yong In, Korea) was performed under
the fluoroscopic guidance. Although this drug has recently
(mid-1999) been withdrawn from clinical use in the U.S.A.
and U.K. because of problems with purity in its manufacture
and on the order of the Food and Drug Administration, we
used urokinase as the thrombolytic agent in this study. With
the patient in prone position, venous access was through the
ipsilateral popliteal vein under the ultrasound guidance. Eight
or 9-Fr vascular sheath (Check-flo; Cook, Bloomington, IN,
U.S.A.) was placed and direct venography was obtained to
estimate the severity and extent of the thrombosis above the
popliteal vein. Before the insertion of infusion catheter for
the thrombolysis, we aspirated part of the filling defect to
curtail the duration and the amount of the thrombolytics with
use of another long, smaller-bore vascular sheath. And then,
a 5-Fr multi-side-hole infusion catheter was inserted through
the sheath. Urokinase was reconstituted by using 500,000 IU
in 100 mL of 0.9% NaCl and delivered in continuous low
dose of 500-2,000 IU/min via thrombolysis catheter. Patients
were systemically treated with heparin during the procedure
through the side arm of the venous sheath after a loading
bolus of 5,000 IU. Partial thromboplastin time values were
obtained at every 4 hr after the start of thrombolytic thera-
py, and the heparin infusion rate was adjusted to maintain
the partial thromboplastin time range with 50-90 sec. Fol-
low-up venography was performed within 12 hr from the
start of thrombolytic therapy. The position of the catheter
was changed to facilitate effective thrombolysis. After throm-
bolysis, further intervention was performed if there was an
underlying venous stenosis of greater than 50%. Intervention
consisted of angioplasty and stent placement. The venous
stenoses were predilated with an 8- or 10-mm-diameter bal-
loon (Ultra-Thin Diamond; Boston Scientific Co., Watertown,
MA, U.S.A.) before stent placement (Wallstent; Boston Sci-
entific Co.). All stents were placed above the inguinal liga-
ment.
Outcome variables 
Immediate technical success was defined as complete reca-
nalization of the vein with less than 30% residual luminal
(area) narrowing (4-6, 9). Immediate clinical success was de-
fined as complete or partial resolution of low extremity pain
and edema. After the procedure, all patients were given anti-
coagulants with a regimen of heparin and, later, orally admin-
istered life-long warfarin, adjusted to maintain a prothrom-
bin time of 2.0 and followed up both clinically and by color
Doppler ultrasound within one month.
RESULTS
Of the 47 patients, catheter-directed thrombolysis was per-
formed in 11 patients (23.4%) with symptoms of less than
10 days’ duration and a diagnosis of iliofemoral DVT con-
firmed by color Doppler ultrasound: 7 with protein C and/or
S deficiency (2 right lower limbs and 5 left lower limbs) and
4 without protein C and/or S deficiency (4 left lower limbs).
After thrombolysis, the diagnosis of IVCS was confirmed in
6 patients: 4 with protein C and/or S deficiency and 2 with-
out protein C and/or S deficiency. Further intervention con-
sisted of angioplasty and stent placement was performed. 
The 4 consecutive patients with IVCS and protein C and/or
S deficiency included in this study were 1 man and 3 women,
aged 43-75 yr (mean, 62.3 yr). Clinical characteristics are sum-
*Location of thrombus means the highest extent of the thrombus. 










1 F/70 Left CIV
� 146/32 5 days
2 M/61 Left CIV 59/27 5 days
3 F/43 Left CIV 37/22 7 days
4 F/75 Left CIV 122/39 10 days
Table 1. Clinical characteristics of 4 patients with iliac vein com-
pression syndrome and protein C and/or S deficiencymarized in Table 1. All patients underwent catheter-direct-
ed thrombolysis and endovascular stents without antecedent
heparin therapy. The mean length of symptoms prior to the
initiation of thrombolysis was 6.8 days, with a range of 5-
10 days. 
Overall, there were immediate technical and clinical success
rates of 100% for treated limbs (Fig. 1). The average dura-
tion of therapy was 39.9 hr (range, 16.5-66.5 hr), and the
average total urokinase dose was 2.8 million IU (range, 1.0
million to 4.7 million IU). There were no complications or
clinically detectable pulmonary emboli. All 4 patients were
asymptomatic at mean clinical follow-up of 11.5 months
(range, 6-20 months). Serial color Doppler ultrasound in all
4 patients showed no evidence of recurrence of DVT and val-
vular insufficiency in the femoral and popliteal vein segments,
using both proximal compression and Valsalva maneuver.
DISCUSSION 
Conventional treatment of iliofemoral DVT has typically
consisted with systemic heparin therapy followed by antico-
agulation with oral warfarin. However, with anticoagulation,
eventual recanalization of the occluded vessel depends solely
on the effectiveness of the patient’s own fibrinolytic system.
Anticoagulation does not protect the patient from the man-
ifestations of post-thrombotic syndrome, which can appear
months to years after the acute episode of DVT (3-8). Long-
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Fig. 1. A 75-yr-old female patient presents with a 10-day history of
left leg pain and severe swelling extending up to the groin. Doppler
ultrasound reveals acute thrombosis extending into the left com-
mon iliac vein. (A) In the prone position, ascending subtraction
venogram demonstrates an acute thrombus extending into the
common iliac vein. (B) After 47 hr of thrombolytic therapy, the vast
majority of the thrombus has been disappeared; the underlying
left common iliac vein stenosis becomes apparent. (C) After angio-
plasty and stent placement, final subtraction venogram shows
complete resolution of iliac vein flow and no residual filling defect.
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term studies in patients with iliofemoral DVT treated with
anticoagulation alone have demonstrated that muscle pump
function and valvular competency are severely compromised
in approximately 95% of patients at 5-yr follow-up despite
improvement in venous outflow (20). The therapeutic goals
for treating the patient with acute DVT include prevention
of pulmonary embolism, restoration of unobstructed blood
flow through the thrombosed segment, prevention of recur-
rent thrombosis, and preservation of venous valve function
(4). Considering that success in the achievement of these clini-
cal goals will minimize the morbidity and mortality associ-
ated with DVT, catheter-directed thrombolysis is a poten-
tially attractive form of therapy: (a) it delivers high concen-
trations of thrombolytic agents directly into the thrombus
while minimizing the potential for a systemic fibrinolytic
effect, (b) it provides the opportunity for the prompt restora-
tion of venous patency and preservation of venous valve func-
tion. This therapy can potentially help prevent long-term
sequelae of DVT with acceptable complication rates. 
Reported clinical series show that lower extremity DVT
occurs three to eight times more frequently on the left when
compared to the right (10, 21-23). Virchow first described
the anatomic relationship of the right common iliac artery
to the left common iliac vein and postulated that the rela-
tionship can produce venous stasis, thus accounting for the
increased frequency of left leg DVT. Thrombosis due to com-
pression of the left common iliac vein by the overlying right
common iliac artery was first characterized by May and Thurn-
er in 1957 (10). May and Thurner examined 430 cadavers
and found 19% to have changes at the junction of the left
common iliac vein with the inferior vena cava, which they
termed the “spur”. In 1967, Cockett et al. reported the first
clinical series of 57 patients presenting with acute iliofemoral
DVT secondary to iliac vein compression and coined it the
“IVCS” (24). However, it is well known that compression of
the left common iliac vein by the right common iliac artery
is a common normal finding during iliocaval venography and
all patients with iliac vein compression do not suffer from
DVT. With the growing interest in catheter-directed throm-
bolysis for extensive lower extremity DVT, IVCS as an anato-
mic risk factor for left-sided iliofemoral thrombosis is being
identified with increasing frequency (25). Prior to the use of
endovascular techniques, the treatment for iliofemoral DVT
due to IVCS remained anticoagulation therapy and/or surgery.
During the past several years, there have been several reports
of favorable results in managing iliofemoral DVT due to IVCS
by endovascular techniques (25, 26). O’Sullivan et al. sug-
gest that endovascular techniques are advantageous for sev-
eral reasons: (a) diagnostic venography allows for direct assess-
ment of the degree of venous obstruction and collateraliza-
tion; (b) large acute thrombus burdens can be cleared with
use of catheter-directed thrombolysis, thus preserving valve
function; (c) obstructive intravenous synechiae and webs (spurs)
can be disrupted by means of angioplasty and stent place-
ment; and (d) the integrity of the compressed iliac vein can
be restored without apparent long-term harm to the over-
riding artery, with acceptable results (25).
The term “hypercoagulable state” is generally used to denote
any conditions in which the normal balance between clot-
ting and anticlotting mechanisms becomes altered in such a
way that the patient is predisposed to thrombus formation.
There are a number of conditions that can lead to a hyperco-
agulable state. Proteins C and S deficiencies are frequently
described as causes of the hypercoagulable states (11-19). Pro-
teins C and S are two of the vitamin K-dependent proteins.
Activated protein C (protein Ca) inactivates factors Va and
VIIIa. Protein C is activated to protein Ca 20,000 times faster
than by thrombin alone through the interaction of throm-
bomodulin and thrombin on the endothelial cell surface (27).
In addition, protein C proteolytically inactivates the inhibitor
to tissue plasminogen activator, thus increasing the natural
fibrinolytic activity of plasma. Protein S is a cofactor for pro-
tein C. The activity of protein Ca is increased several orders
of magnitude by its nonenzymatic cofactor protein S. Pro-
teins C and S deficiencies may be seen in both congenital and
acquired forms. They are inherited in an autosomal domi-
nant manner. In the congenital conditions, those homozy-
gous for protein C deficiency usually die in infancy, while
those heterozygous have antigenic protein C levels less than
60% of normal and present with recurrent venous throm-
bosis. Thrombotic events are often precipitated by another
factor, such as trauma, surgery, or childbirth. Although the
only established treatment for patients with thrombotic events
is heparin therapy followed by life-long warfarin therapy,
catheter-directed thrombolysis for acute iliofemoral DVT
may be safe and effective in patients with protein C and/or S
deficiency (9). Furthermore, in patients undergoing coronary
thrombolysis, Gruber et al. showed an 11-fold increase in
protein Ca during thrombolysis (28). They concluded that
thrombolytic therapy generates at least two potent antithrom-
botic factors in the circulation, namely the fibrinolytic enzyme,
plasmin, and the anticoagulation enzyme, protein Ca. There-
fore, we speculate that endogenous protein Ca generated dur-
ing thrombolysis has more potent antithrombotic effects in
patients with DVT and protein C and/or S deficiency. Pro-
tein Ca may help prevent rethrombosis during or after throm-
bolysis.
In this small study, 4 with protein C and/or S deficiency
and 2 without protein C and/or S deficiency showed IVCS
after thrombolysis. Further intervention consisted of angio-
plasty and stent placement was performed successfully in all
treated limbs without complications or clinically detectable
pulmonary emboli. During catheter-directed thrombolysis,
major bleeding complications are primarily related to the
catheter insertion site (4). Cautious needle access under the
ultrasound guidance is mandatory to avoid inadvertent punc-
ture of adjacent vessels such as the popliteal artery. A theo-
retical consideration with catheter-directed thrombolysis isIVCS in Protein C/S Deficiency 733
dislodgement of significant thrombotic material, leading to
a pulmonary embolus. There is a relatively high incidence
of asymptomatic pulmonary emboli in iliac venous throm-
bosis, as shown by scintigraphy (29). Although the true preva-
lence of pulmonary emboli is unknown in our study, there
were no clinically significant cases of pulmonary emboli result-
ing in increasing dyspnea or arterial oxygen desaturation.
We did not perform scintigraphy and insert caval filters. 
In summary, the presence of protein C and/or S deficiency
may influence clinical management. In addition to younger
patients, other patients who presented with acute, massive
iliofemoral DVT not precipitated by other risk factors might
benefit from hypercoagulability testing. If there are no con-
traindications, patients with DVT associated with this hyper-
coagulability should be treated with full anticoagulation in-
definitely. Considering that compression of the left common
iliac vein by the right common iliac artery is a common nor-
mal finding during iliocaval venography, protein C and/or S
deficiency may be an important predisposing factor for acute
iliofemoral DVT secondary to IVCS. Also, endovascular tech-
niques for the treatment of these patients require further eval-
uation with full clinical study and long-term follow up, and
this presentation shows only the initial experience of this
therapeutic modality as a safe and effective method for treat-
ing acute iliofemoral DVT with IVCS and protein C and/or
S deficiency.
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